High RSF1 protein expression is an independent prognostic feature in prostate cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203–213.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Jr, Tangen CM. Prostate cancer–uncertainty and a way forward. N Engl J Med. 2012;367(3):270–271.
   PubMed Web of Science ®Google Scholar
• Lee TH, Elledge SJ, Butel JS. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J Virol. 1995;69(2):1107–1114.
   PubMed Web of Science ®Google Scholar
• Shamay M, Barak O, Shaul Y. HBXAP, a novel PHD-finger protein, possesses transcription repression activity. Genomics. 2002;79(4):523–529.
   PubMed Web of Science ®Google Scholar
• Shih I-M, Sheu JJ-C, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A. 2005;102(39):14004–14009.
   PubMed Web of Science ®Google Scholar
• Zhang X, Fu L, Xue D, et al. Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer. Virchows Arch. 2017;470(5):553–560.
   PubMed Web of Science ®Google Scholar
• Xie C, Fu L, Xie L, et al. Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma. Tumor Biol. 2014;35(8):7595–7601.
   PubMedGoogle Scholar
• Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumor Biol. 2012;33(5):1485–1491.
   PubMedGoogle Scholar
• Tai HC, Huang HY, Lee SW, et al. Associations of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma. J Clin Pathol. 2012;65(3):248–253.
   PubMed Web of Science ®Google Scholar
• Hu BS, Yu HF, Zhao G, et al. High RSF-1 expression correlates with poor prognosis in patients with gastric adenocarcinoma. Int J Clin Exp Pathol. 2012;5(7):668–673.
   PubMed Web of Science ®Google Scholar
• Lin CY, Tian YF, Wu LC, et al. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation. J Clin Pathol. 2012;65(8):687–692.
   PubMed Web of Science ®Google Scholar
• Liang PI, Wu LC, Sheu JJ, et al. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma. J Clin Pathol. 2012;65(9):802–807.
   PubMed Web of Science ®Google Scholar
• Choi JH, Sheu JJ, Guan B, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69(4):1407–1415.
   PubMed Web of Science ®Google Scholar
• Fang FM, Li CF, Huang HY, et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol. 2011;178(5):2407–2415.
   PubMed Web of Science ®Google Scholar
• Sheu JJ, Choi JH, Yildiz I, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res. 2008;68(11):4050–4057.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang Y, Zhang Y, et al. Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker. Tumor Biol. 2014;35(6):5771–5776.
   PubMedGoogle Scholar
• Schlomm T, Iwers L, Kirstein P, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008;21(11):1371–1378.
   PubMed Web of Science ®Google Scholar
• Sauter G, Steurer S, Clauditz TS, et al. Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol. 2016;69(4):592–598.
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallionimeni A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–847.
   PubMed Web of Science ®Google Scholar
• Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011;17(18):5878–5888.
   PubMed Web of Science ®Google Scholar
• Krohn A, Seidel A, Burkhardt L, et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol. 2013;231(1):130–141.
   PubMed Web of Science ®Google Scholar
• Burkhardt L, Fuchs S, Krohn A, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013;73(9):2795–2805.
   PubMed Web of Science ®Google Scholar
• Kluth M, Hesse J, Heinl A, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol. 2013;26:975–983.
   Google Scholar
• Kluth M, Amschler NN, Galal R, et al. Deletion of 8p is an independent prognostic parameter in prostate cancer. Oncotarget. 2017;8:379–392.
   PubMedGoogle Scholar
• Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181(2):401–412.
   PubMed Web of Science ®Google Scholar
• Kluth M, Runte F, Barow P, et al. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. Int J Cancer. 2015;137(10):2354–2363.
   PubMed Web of Science ®Google Scholar
• Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013;23(2):159–170.
   PubMed Web of Science ®Google Scholar
• Kluth M, Harasimowicz S, Burkhardt L, et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int J Cancer. 2014;135(6):1369–1380.
   PubMed Web of Science ®Google Scholar
• Kluth M, Graunke M, Moller-Koop C, et al. Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget. 2016;7(52):86339–86349.
   PubMedGoogle Scholar
• Minner S, Jessen B, Stiedenroth L, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res. 2010;16(5):1553–1560.
   PubMed Web of Science ®Google Scholar
• Aydin OZ, Vermeulen W, Lans H. ISWI chromatin remodeling complexes in the DNA damage response. Cell Cycle. 2014;13(19):3016–3025.
   PubMed Web of Science ®Google Scholar
• Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer. 2011;11(1):507.
   PubMedGoogle Scholar
• Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–648.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.
   PubMed Web of Science ®Google Scholar
• Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67(18):8504–8510.
   PubMed Web of Science ®Google Scholar
• Min S, Choi YW, Yun H, et al. Post-translational regulation of the RSF1 chromatin remodeler under DNA damage. Mol Cells. 2018;41(2):127–133.
   PubMed Web of Science ®Google Scholar
• Sheu JJ, Guan B, Choi JH, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 2010;285(49):38260–38269.
   PubMed Web of Science ®Google Scholar
• Wilczak W, Wittmer C, Clauditz T, et al. Marked prognostic impact of minimal lymphatic tumor spread in prostate cancer. Eur Urol. 2018;74(3):376–386.
   PubMed Web of Science ®Google Scholar
• Egevad L, Ahmad AS, Algaba F, et al. Standardization of Gleason grading among 337 European pathologists. Histopathology. 2013;62(2):247–256.
   PubMed Web of Science ®Google Scholar